By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. Who? 2010 Jul;19(7):715-21. doi: 10.1002/pds.1954.Expert Opin Drug Saf. Thiazolidinediones, when used as monotherapy, are not associated with hypoglycemia, as they do not increase insulin secretion. Epub 2008 Sep 2.Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, Marrero DG, Hsiao VC, Tseng CW, Mangione CM, Lasser NL, Crosson JC, Herman WH.Pharmacoepidemiol Drug Saf. Diabetes Care 26: 2983 –2989, 2003. Free PMC article Thiazolidinediones (TZDs) are a class of compounds specifically designed to reduce insulin resistance by increasing peripheral glucose disposal and decreasing glucose production.The EIDOS and DoTS descriptions of the risk of fractures due to thiazolidinediones are shown in In 55 patients with type 2 diabetes, mean age 66 years, who were randomized to pioglitazone 15–30 mg/day or metformin for 12 months, osteocalcin concentrations fell significantly in those taking pioglitazone at 6 months, but were nearly back to baseline concentrations at 12 months [Data from ADOPT (A Diabetes Outcome Prevention Trial), in which 4360 patients with type 2 diabetes were randomized to rosiglitazone, metformin, or glibenclamide have shown an increased number of fractures in women taking rosiglitazone [The UK-based General Practice Research Database (GPRD) was used to identify people aged 30–79 years with type 2 diabetes (n = 66 696), of whom 16 648 had not used insulin or oral hypoglycemic drugs and 50 048 had received at least one prescription for an oral agent [Bone turnover has been analysed in a 14-week, double-blind, randomized study in 50 postmenopausal women taking rosiglitazone 8 mg/day or placebo [The increased risk of fractures has been confirmed in the RECORD study, in which the cardiovascular safety of rosiglitazone was investigated in 2220 patients with type 2 diabetes, aged 40–75 years, who took rosiglitazone in combination with metformin or a sulfonylurea and were compared with 2227 patients who took metformin and a sulfonylurea [Data from a prospective cohort study of 84 339 patients in Canada, mean age 59 years, 43% women, have confirmed the increased risk among women of peripheral fractures when taking thiazolidinediones; the NNTData from a large US health-care organization have been used to identify 4511 patients, mean age 57 years, who had used a thiazolidinedione; for comparison with 14 559 who had not, mean age 58 years [In an analysis of Taiwan Insurance claims 18 003 patients with type 2 diabetes who had had a fracture and 90 015 matched controls were identified [In addition to their contribution as insulin sensitizers for glycemic control, the thiazolidinediones potentially have beneficial effects on endothelial function, atherogenesis, fibrinolysis, and ovarian steroidogenesis.
Insulin-resistant type 2 diabetes is the co-existence of two separate metabolic abnormalities: a… This site needs JavaScript to work properly. It remains unclear if these anti-inflammatory properties are unique to thiazolidinediones specifically or result from improvements in insulin resistance.TZDs (pioglitazone, rosiglitazone) are PPARγ ligands that induce binding of PPARγ with one or more coactivator proteins to a PPAR response element (PPRE), promoting transactivation of a large number of target genes involved in fatty acid uptake and storage, glucose uptake, adipocyte differentiation, and adipocyte-derived cytokine production. Name must be less than 100 characters
Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
Thiazolidinediones are now generic and less costly than pharmaceutical company-promoted therapies.
2020 May 29;11:1043. doi: 10.3389/fimmu.2020.01043.
Meier C, Kraenzlin ME, Bodmer M, et al.
ScienceDirect ® is a registered trademark of Elsevier B.V.URL: https://www.sciencedirect.com/science/article/pii/B9780444537171015365URL: https://www.sciencedirect.com/science/article/pii/B9780128012383108670URL: https://www.sciencedirect.com/science/article/pii/B008045044X001796URL: https://www.sciencedirect.com/science/article/pii/B9780128029497000079URL: https://www.sciencedirect.com/science/article/pii/B9780323551380000127URL: https://www.sciencedirect.com/science/article/pii/B9780123983138000014URL: https://www.sciencedirect.com/science/article/pii/B978032339307200031XURL: https://www.sciencedirect.com/science/article/pii/B9780123786302000359URL: https://www.sciencedirect.com/science/article/pii/B9780323074452000124Therapeutic Areas I: Central Nervous System, Pain, Metabolic Syndrome, Urology, Gastrointestinal and CardiovascularPharmacogenetic Factors That Affect Drug Metabolism and Efficacy in Type 2 Diabetes MellitusJaakkola et al., 2006; Budde et al., 2003; Cox et al., 2000Hammarstedt, Sopasakis, Gogg, Jansson, & Smith, 2005; Pajvani et al., 2004; Phillips et al., 2009Pharmacology and Therapeutics for Dentistry (Seventh Edition)Encyclopedia of Biological Chemistry (Second Edition)Elsevier's Integrated Review Pharmacology (Second Edition)ScienceDirect ® is a registered trademark of Elsevier B.V.